To the latter point, a broad medical analysis published in PloS Medicine (9/18/12) looked at the JUPITER trial conducted in 2009—a trial that suggested Crestor cut the risk of blood clots in healthy adults in half. JUPITER studied 17,800 participants taking either Crestor or placebo. After two years, 60 participants in the placebo group developed a venous thrombo-embolism v. 34 in the Crestor issues group.
However University of Oxford researcher Kazem Rahimi found those numbers to be low, so Rahimi and colleagues performed a meta analysis of no fewer than 29 published and unpublished trials involving more than 100,000 participants in total.
They found blood clots occurred in 1.0 per cent of participants on placebo v. 0.9 percent taking a statin such as Crestor. "We were unable to confirm the large proportional reduction in (clot) risk," the researchers said, adding that a more modest but perhaps clinically worthwhile effect could not be ruled out.
As for Crestor diabetes the debate continues, even in the face of new data from Harvard researchers that suggests the cardiovascular benefits of Crestor and statins in general outweigh any risk for the development of diabetes. Lead researcher Dr. Paul Ridker, director of the Center for Cardiovascular Disease Prevention at Brigham and Women's Hospital in Boston, noted in a paper published in The Lancet (8/9/12) that the cardiovascular benefits of statins such as Crestor far outweigh the risk for diabetes, even amongst those who are prone to diabetes risk.
The research team's intent was to put the focus on all statins. However, the trial from which data was culled was based only on Crestor, and according to Consumer Health News (8/9/12) was the first trial to identify the possibility for Crestor diabetes.
In the end, the cardiovascular benefits won the day over concern for diabetes risk. And while researchers studying the Crestor side effects noted no significant risk for diabetes in healthy participants, at the same time they acknowledged the risk for Crestor diabetes was influenced by an individual's existing risk for diabetes.
To that point, the study found that individuals with a single pre-existing risk factor for diabetes showed a 28 percent increase in diabetes risk. The risk was such that the US Food and Drug Administration (FDA) required the makers of Crestor and other statins to include the risk on product labeling.
There are other risks associated with Crestor, including Crestor cardiomyopathy and Crestor rhabdoymylosis, a serious condition involving the breakdown of muscular tissue into the bloodstream. But those risks are quite rare. The diabetes risk, in contrast, is one that has had a lot of people concerned, a fact not lost on Dr. Ridker.
"Earlier this year, concern was raised that patients taking statins had an increased risk of developing diabetes, and on that basis many patients stopped taking their medications," Ridker said in comments published in Consumer Health News.
READ MORE CRESTOR LEGAL NEWS
Natural health advocates note that often cholesterol can be managed without medication, through improvements in diet, lifestyle and regular exercise and thus dispelling the need for medication save for those patients with serious issues. Meanwhile, a Crestor lawsuit will claim that a plaintiff adversely affected by Crestor either didn't need to take the medication at all, or was not properly informed of the risk.